Report Overview
The Australia Legal Cannabis Market size is expected to be worth around US$ 3012.4 Million by 2035 from US$ 879.6 Million in 2025, growing at a CAGR of 13.1% during the forecast period 2026-2035.
The Australia Legal Cannabis Market is emerging as a dynamic and rapidly evolving sector, supported by changing regulatory frameworks, increasing public awareness, and growing acceptance of cannabis-based products across medical and industrial applications. Legal cannabis in Australia primarily includes medicinal cannabis products prescribed for approved therapeutic conditions, while industrial hemp cultivation continues to expand for use in food, fiber, and wellness products.
The market is benefiting from a rising number of patients accessing medicinal cannabis through authorized healthcare channels, alongside ongoing investments in cultivation, manufacturing, and research facilities. Government oversight and quality standards have strengthened consumer confidence, encouraging broader adoption of regulated cannabis products. Technological advancements in cultivation methods, product formulation, and distribution networks are further contributing to market expansion.
Australia's favorable climate and agricultural expertise also position the country as a potential exporter of high-quality cannabis products to international markets where regulations permit trade. In addition, increasing clinical research activities are generating valuable evidence regarding the therapeutic potential of cannabis-based treatments.
As regulatory clarity improves and industry infrastructure matures, the Australia Legal Cannabis Market is expected to witness sustained growth, creating opportunities for cultivators, manufacturers, healthcare providers, investors, and research organizations throughout the forecast period.
Click here for more information: https://market.us/report/australia-legal-cannabis-market/
Key Takeaways
- In 2025, the Australia Legal Cannabis Market was valued at US$ 879.6 Million and is projected to reach US$ 3,012.4 Million by 2035, expanding at a CAGR of 13.1% during the forecast period.
- By source, the market is segmented into hemp and marijuana, with hemp leading the segment and accounting for 54.1% of the total market share in 2025.
- Based on derivative, the market is categorized into CBD (Cannabidiol), THC (Tetrahydrocannabinol), and others. Among these, the CBD segment dominated the market, capturing 56.1% of the overall share.
- By application, the market is divided into medical, recreational, and industrial segments. The medical application segment held the largest market share, accounting for 76.4% of total revenue in 2025.
Key Market Segments
- By Source
- Hemp
- Hemp CBD Oil
- Supplements
- Industrial Hemp
- Marijuana
- Flower
- Oil
- Tinctures
- By Derivative
- CBD (Cannabidiol)
- THC (Tetrahydrocannabinol)
- Others
- By Application
- Medical
- Chronic Pain
- Cancer
- Anxiety
- Arthritis
- Epilepsy
- PTSD
- Others
- Recreational
- Legalized in ACT
- Restricted elsewhere
- Industrial
Market Key Players
- Vitura Health Limited (Dominant digital health and distribution platform)
- Little Green Pharma (LGP)
- Bioxyne
- Green Farmers (Biortica Agrimed)
- ECS Botanics
- Tasmanian Botanics
- Cann Group
- Zelira Therapeutics
- AusCann Group Holdings Ltd
- Bod Science
- Althea Group
- Incannex Healthcare ## Market Dynamics
Driver
One of the primary drivers of the Australia Legal Cannabis Market is the increasing patient access to medicinal cannabis through regulated healthcare pathways. Since the legalization of medicinal cannabis in 2016, Australia has established structured access mechanisms through the Therapeutic Goods Administration (TGA), including the Special Access Scheme (SAS) and Authorized Prescriber pathways. These frameworks have significantly improved availability for patients suffering from chronic pain, epilepsy, multiple sclerosis, chemotherapy-induced nausea, and palliative care needs. The TGA reports that medicinal cannabis approvals have grown substantially since 2016, reflecting broader acceptance among healthcare professionals and patients. Additionally, only a limited number of cannabis-based medicines are currently listed on the Australian Register of Therapeutic Goods (ARTG), creating continued demand for regulated unapproved products accessed through SAS and AP pathways. Increasing physician awareness, patient demand for alternative therapies, and ongoing clinical investigations are further supporting market expansion. As healthcare providers gain more experience with cannabinoid-based treatments, prescription volumes are expected to rise, reinforcing sustained growth across Australia's legal cannabis sector.
Trend
A notable trend in the Australia Legal Cannabis Market is the increasing commercialization of industrial hemp across multiple industries. Industrial hemp cultivation is permitted under state licensing frameworks and is defined by very low tetrahydrocannabinol (THC) levels, generally not exceeding 1% THC. Hemp-derived products are gaining popularity in food, nutrition, cosmetics, textiles, construction materials, and sustainable packaging applications. Since hemp seed foods were approved for sale in Australia in 2017, manufacturers have expanded offerings of hemp protein powders, oils, seeds, and functional foods. Government agricultural agencies have highlighted hemp's versatility, noting its use in hempcrete construction materials, fiber production, and environmentally friendly industrial products. The crop also offers sustainability advantages due to its relatively low input requirements and potential carbon sequestration benefits. Several Australian states are actively supporting hemp cultivation through licensing programs and agricultural development initiatives. As consumers increasingly seek plant-based and sustainable products, hemp is emerging as a key growth segment within the broader legal cannabis industry, driving investment throughout the agricultural and manufacturing value chain.
Restraint
Despite strong growth prospects, regulatory complexity remains a significant restraint for the Australia Legal Cannabis Market. Most medicinal cannabis products available in Australia are classified as unapproved therapeutic goods and must be accessed through specific regulatory pathways rather than standard pharmaceutical channels. Healthcare practitioners are required to obtain approvals or authorizations before prescribing many cannabis products, creating administrative burdens that can limit adoption. Additionally, medical organizations and regulators continue to emphasize the need for stronger clinical evidence supporting cannabis use across various indications. Concerns regarding inconsistent prescribing practices have led the Australian Health Practitioner Regulation Agency (Ahpra) and the TGA to strengthen oversight and issue prescribing guidance. Reports indicate that regulators have investigated high-volume prescribing practices and introduced additional safeguards to protect patient safety. Furthermore, uncertainty surrounding reimbursement, product standardization, and long-term clinical outcomes may discourage some healthcare providers from prescribing cannabis therapies. These factors collectively create barriers to broader market penetration and may slow growth despite increasing public interest and patient demand.
Opportunity
Australia possesses substantial opportunities to expand its legal cannabis industry through domestic cultivation, research, and international exports. The country's advanced agricultural sector, favorable growing conditions, and strong regulatory framework position it well to become a significant producer of high-quality cannabis products. Increasing investment in licensed cultivation facilities and processing infrastructure is supporting the development of a local supply chain. Industry data indicate that domestic medicinal cannabis production has risen considerably in recent years, demonstrating the sector's growing capacity. At the same time, government-regulated cultivation programs and ongoing clinical research activities are generating new opportunities for product innovation and evidence-based applications. Expanding research into cannabinoid therapies for neurological disorders, chronic pain, mental health conditions, and other medical indications could support future regulatory approvals and market growth. Industrial hemp also presents export opportunities in food, fiber, and sustainable construction materials. As global demand for regulated cannabis products continues to increase, Australia has the potential to strengthen its position as a trusted supplier of premium cannabis and hemp-derived products for both domestic and international markets.
Conclusion
The Australia Legal Cannabis Market is poised for substantial growth, expanding from US$ 879.6 Million in 2025 to approximately US$ 3,012.4 Million by 2035, at a CAGR of 13.1%. Market expansion is being driven by increasing acceptance of medicinal cannabis, evolving regulatory frameworks, growing patient access, and rising investment in cannabis cultivation and product development. The dominance of the hemp source segment (54.1%) highlights the growing importance of hemp-based applications, while CBD products (56.1%) continue to lead demand due to their broad therapeutic and wellness applications. Additionally, the medical application segment (76.4%) remains the primary revenue contributor, reflecting the strong role of cannabis in healthcare and patient treatment programs. As research advances and regulatory clarity improves, Australia is well-positioned to strengthen its domestic cannabis industry while expanding export opportunities. Continued innovation, healthcare integration, and industry investment are expected to support long-term market development, making legal cannabis one of the country's most promising emerging sectors over the forecast period.
Top comments (0)